Enliven Therapeutics, Inc. $ELVN Stock Purchased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 14.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,325,740 shares of the company’s stock after purchasing an additional 163,956 shares during the period. Pictet Asset Management Holding SA owned 1.81% of Enliven Therapeutics worth $60,772,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. KBC Group NV acquired a new stake in shares of Enliven Therapeutics during the 1st quarter worth approximately $38,000. State of Wyoming acquired a new position in Enliven Therapeutics in the second quarter valued at approximately $96,000. Sterling Capital Management LLC lifted its holdings in Enliven Therapeutics by 1,180.7% in the third quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock valued at $88,000 after buying an additional 1,771 shares during the period. FNY Investment Advisers LLC bought a new position in Enliven Therapeutics in the second quarter valued at approximately $126,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Enliven Therapeutics in the third quarter valued at approximately $172,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

ELVN has been the subject of several recent research reports. HC Wainwright upped their target price on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 19th. The Goldman Sachs Group increased their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Barclays started coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price target on the stock. Stifel Nicolaus lifted their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Mizuho upped their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $51.55 on Tuesday. The company’s 50 day simple moving average is $47.13 and its 200 day simple moving average is $43.20. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the sale, the director directly owned 13,000 shares in the company, valued at $606,710. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 31,054 shares of company stock worth $1,493,823. Insiders own 3.00% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth.

The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2.

Enliven is based in Boulder, Colorado.